Nov 11, 2019
Wet Age-Related Macular Degeneration Market by Product, by Distribution Channel, by Age Group, by Route of Administration, by End User, by Geography Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024
Nov 06, 2019
Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.
Oct 11, 2019
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
Oct 08, 2019
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Aug 20, 2019
BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME
Aug 06, 2019
Global Wet Age-Related Macular Degeneration Markets, 2014-2018 & 2019-2024 - Positive Clinical Trial Results and Increasing Approvals for Pipeline Drugs
Apr 02, 2019
Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol
Mar 14, 2019
Intravitreal (IVT) Injectables Market is Expected to Rake in Revenues Worth US$ 4,350 Mn by 2028 End
Dec 21, 2018
Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate
Oct 27, 2018
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
Oct 26, 2018
Easier, Potentially More Effective Treatment for Blinding Eye Disease Shows Promise in Clinical Trial
Oct 25, 2018
EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Sep 13, 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Aug 17, 2018
FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Aug 01, 2018
RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring
Jul 19, 2018
Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration
May 21, 2018
http://www.navilas.com New Website Informs Diabetics about the Navigated Laser Treatment of Vision-Threatening Retinal Diseases
Mar 19, 2018
Proliferative Diabetic Retinopathy Market to Each Roughly US$ 1,000 Million by 2026-end: Transparency Market Research
Feb 12, 2018
Santen Presents Phase I/II Data on DE-122 (Carotuximab) in Patients with Refractory Wet Age-Related Macular Degeneration
Feb 06, 2018
Global Retinal Disorders Landscape Report 2017